PRRUF — IMMUTEP Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1506184 ·
Last close
$0.03
Market Cap
$44.21M
52W High
$0.33
52W Low
$0.03
ADV30
83
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | 63,672,558 | — |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | — | — | — | — | 147,201,896 | 72,747,858 | 48,303,108 |
| Mar 2025 | — | — | — | — | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$-486,351,557
Inventory
—
Receivables
$37,520,366
ST Investments
$26,381,641
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$19,934,102
EBITDA
$-79,403,952
Free Cash Flow
$-36,994,360
Enterprise Value
$-11,971,481
Total Cash
$68,873,040
Total Debt
$1,047,526
Shares Out
1,473,721,306
Trailing EPS
$-0.04
Book Value
$0.05
ROE
-77.3%
ROA
-42.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 14,556,923 | -81,592,146 | -79,304,563 | 83,267,229 | 21,734,183 | 61,533,046 | — |
| Jun 2025 | — | — | — | — | — | — | — |
| Jun 2024 | 0 | -46,557,462 | -42,716,625 | 201,579,281 | 12,057,539 | 189,521,742 | — |
| Jun 2023 | 0 | -41,431,305 | -39,896,348 | 147,448,990 | 10,979,601 | 136,469,389 | — |
| Jun 2022 | 170,369 | -33,837,338 | -32,210,826 | 102,169,550 | 8,092,184 | 94,077,366 | -43,944,386 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HOWL | Werewolf Therapeutics, Inc. | $44.23M | $0.91 | — |
| GRCE | Grace Therapeutics, Inc. | $42.91M | $2.04 | — |
| NSRX | Nasus Pharma Ltd | $42.52M | $3.63 | — |
| SCYX | SCYNEXIS INC | $41.99M | $4.22 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $41.58M | $2.83 | — |
News headlines (Yahoo Finance, 1h cache)
Immutep Receives ~A$0.86 Million R&D Tax Incentive
2026-09-30 12:00 · Yahoo
Change to American Depositary Share Ratio
2026-09-21 12:00 · Yahoo
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
2026-09-11 12:00 · Yahoo
Immutep Quarterly Activities Report Q4 FY26
2026-07-30 12:00 · Yahoo
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
2026-07-24 12:00 · Yahoo
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsi
2026-07-21 17:00 · Yahoo
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
2026-07-14 12:00 · Yahoo
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
2026-07-13 12:00 · Yahoo
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
2026-06-04 12:00 · Yahoo
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
2026-05-28 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.